Profiel
Kathleen Gallagher is President, Chief Executive Officer & Director at Atrium Therapeutics, Inc. since 2026.
Formerly, Ms. Gallagher was Head-Communications at Merrimack Pharmaceuticals, Inc. from 2003 to 2016 and held the position of VP-Investor Relations & Corporate Communications at Akcea Therapeutics, Inc. Education includes undergraduate studies at Boston University.
Actieve functies van Kathleen Gallagher
| Bedrijven | Functie | Begin |
|---|
Eerdere bekende functies van Kathleen Gallagher
| Bedrijven | Functie | Einde |
|---|---|---|
| AVIDITY BIOSCIENCES, INC. | Investor Relations Contact | - |
| MERRIMACK PHARMACEUTICALS | Public Communications Contact | 01-10-2016 |
| AKCEA THERAPEUTICS, INC. | Investor Relations Contact | - |
Opleiding van Kathleen Gallagher
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Avidity Biosciences, Inc.
Avidity Biosciences, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that provides research and development, administrative & investment services | Health Technology |
Boston University
Boston University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes drugs for the treatment of immunological & autoimmune diseases and cancer | Health Technology |
Akcea Therapeutics, Inc.
Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for cardiometabolic lipid disorders | Health Technology |
















